Axogen, Inc.AXGNEarnings & Financial Report
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is...
AXGN Q1 FY2026 Key Financial Metrics
Revenue
$61.5M
Gross Profit
$46.2M
Operating Profit
$12.4M
Net Profit
$-19.6M
Gross Margin
75.2%
Operating Margin
20.2%
Net Margin
-31.9%
YoY Growth
26.6%
EPS
$-0.38
Axogen, Inc. Q1 FY2026 Financial Summary
Axogen, Inc. reported revenue of $61.5M (up 26.6% YoY) for Q1 FY2026, with a net profit of $-19.6M (down 410.8% YoY) (-31.9% margin). Cost of goods sold was $15.3M, operating expenses totaled $33.8M.
Key Financial Metrics
| Total Revenue | $61.5M |
|---|---|
| Net Profit | $-19.6M |
| Gross Margin | 75.2% |
| Operating Margin | 20.2% |
| Report Period | Q1 FY2026 |
Axogen, Inc. Annual Revenue by Year
Axogen, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $225.2M).
Axogen, Inc. Quarterly Revenue & Net Profit History
Axogen, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $61.5M | +26.6% | $-19.6M | -31.9% |
| Q4 FY2025 | $59.9M | +21.3% | $-13.2M | -22.0% |
| Q3 FY2025 | $60.1M | +23.5% | $708.0K | 1.2% |
| Q2 FY2025 | $56.7M | +18.3% | $579.0K | 1.0% |
| Q1 FY2025 | $48.6M | +17.4% | $-3.8M | -7.9% |
| Q4 FY2024 | $49.4M | +15.1% | $450.0K | 0.9% |
| Q3 FY2024 | $48.6M | +17.9% | $-1.9M | -3.8% |
| Q2 FY2024 | $47.9M | +25.6% | $-1.9M | -4.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.9M | $48.6M | $49.4M | $48.6M | $56.7M | $60.1M | $59.9M | $61.5M |
| YoY Growth | 25.6% | 17.9% | 15.1% | 17.4% | 18.3% | 23.5% | 21.3% | 26.6% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $188.9M | $192.0M | $203.7M | $196.2M | $205.5M | $216.4M | $221.7M | $289.5M |
| Liabilities | $93.2M | $92.6M | $99.8M | $90.8M | $93.2M | $95.6M | $92.8M | $44.7M |
| Equity | $95.7M | $99.4M | $103.9M | $105.4M | $112.3M | $120.8M | $128.8M | $244.8M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $4.2M | $3.9M | $8.7M | $-13.2M | $7.7M | $3.2M | $3.0M |